On Wednesday, U.S. District Court Judge Tanya Walton Pratt entered final judgment prohibing a group of pharmaceutical companies from selling a generic version of Lilly’s antidepressant drug, Cymbalta®. The ruling also stipulated that the U.S. Food and Drug Administration be ”notified that the defendants were no longer seeking approval for an abbreviated new drug application.” The final judgment will maintain U.S. exclusivity for Lilly’s Cymbalta® throughout the drug’s patented life. Eli Lilly and Company is represented by Finnegan.